Autologus blood/marrow transplantation: Autologous stem cell transplantation for malignant lymphomas

P. Reményi, T. Masszi, G. Kriván, V. Goda, M. Réti

Research output: Article

1 Citation (Scopus)


From December 1995 to April 1998, 20 consecutive adult patients suffering from chemosensitive relapse of Hodgkin's or non-Hodgkin lymphoma (11 Hodgkin, 9 non-Hodgkin Lymphoma) received autologous stem cell transplantation. The median follow up period is 15 months (range 6-28). The overall survival is 18/20 (90 %), the event free survival is 13/20 (65%). None of the patients died of transplant related cause.

Original languageEnglish
Pages (from-to)S104-S106
JournalBone Marrow Transplantation
Issue numberSUPPL. 4
Publication statusPublished - dec. 1 1998


ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this